April 26th 2024
New data reinforced the safety and tolerability profile of this antiretroviral therapy for this patient population who are virologically suppressed.
HIV and Aging in the Era of Antiretroviral Therapy: Considerations in Clinical Care
October 28th 2022With the population of adults with HIV growing older, incorporating age-based screenings, comprehensive assessments, and morbidity management into routine HIV care is essential in improving health outcomes and quality of life.
Read More
PREMISE: Bacterial STI Prophylaxis Failed to Cut Infection Rates for Pregnant Women Living With HIV
October 19th 2022The phase IIb trial evaluated whether adding a novel regimen of monthly azithromycin to a daily dose of trimethoprim-sulfamethoxazole would decrease the rate of STI at time of delivery among pregnant women living with HIV in Cameroon.
Read More
Gender-Affirming Care in Persons Living With HIV
Gender-affirming hormone therapy (GAHT) therapy consists of administration of exogenous hormones and suppression of endogenous hormone production, with the goal of obtaining characteristics more congruent with an individual’s gender identity. Here is a review of these therapies and consideration for PrEP and the risks associated with HIV in this diverse population.
Read More
Incidence of STIs Stabilized Among Gay and Bisexual Men Using HIV PrEP
August 9th 2022After widespread implementation of HIV pre-exposure prophylaxis (PrEP) among gay and bisexual men in Australia, population-level incidence of chlamydia and gonorrhea stabilized, allaying fears that PrEP would lead to a rise in STIs, a recent study found.
Read More